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Abstract 
Background: Autoimmune hemolytic anemia (AIHA), a life-threatening anemia with rapid onset, is caused by 
autoantibody directed to self red blood cells (RBCs). Currently, mechanisms underlying AIHA pathogenesis are largely 
undefined. Here we explored the correlation of IL-33 with AIHA disease activity and evaluated IL-33 based therapeu-
tics in AIHA treatment.
Methods:  Thirty patients diagnosed with AIHA of warm-type autoantibodies without treatment were enrolled and 
followed up for 6 months. Levels of cytokines including IL-33, IL-4, IL-6 and IL-13 was determined with ELISA. AIHA 
disease activity was presented by levels of reticulocyte count, hemoglobin and lactate dehydrogenase. Serum RBC-
bound IgG autoantibody was detected using anti-IgG antibody with flow cytometry. To evaluate the effect of IL-33 
blockade on AIHA development, groups of B6 mice were immunized with rat RBCs plus recombinant IL-33 protein or 
IL-33 neutralizing antibody respectively and detected for levels of anti-RBC antibody, frequency of reticulocytes and 
destruction of transfused syngeneic mouse RBCs.
Results: Serum level of IL-33 was higher in AIHA patients compared with healthy individuals. Of interest, serum IL-33 
was positively correlated with AIHA disease activity and sensitive to their changes in AIHA patients under clinical 
management. Mechanistically, IL-33 could promote the production of anti-RBC autoantibody. Serum IL-33 was closely 
associated with serum anti-RBC autoantibody and sensitive to their changes in AIHA patients. Accordingly, blockade 
of IL-33 interfered with AIHA incidence and ameliorated disease activity. Vice vasa, enforced IL-33 promoted AIHA 
incidence and disease activity.
Conclusions: IL-33 was a potential biomarker for monitoring disease activity and therapeutic response in AIHA 
patients. Targeting IL-33 was a promising strategy for controlling autoantibody production in AIHA patients.
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Background
Autoimmune hemolytic anemia (AIHA), a life-threat-
ening anemia with rapid onset, is defined by enhanced 
destruction of red blood cells (RBCs) because of the pro-
duction and accumulation of anti-RBC autoantibodies 
[1, 2]. AIHA can be classified by optimal temperature at 
which the anti-RBC autoantibodies bind to a patient’s 
RBCs, and warm AIHA accounts for about 80  % of all 
AIHA cases [3]. In patients with warm AIHA, the anti-
RBC autoantibodies are usually IgG type and bind opti-
mally to RBCs at 37 °C, causing RBC destruction by tissue 
macrophages [1, 4–6]. Currently, therapeutic options for 
patients with AIHA are still limited due to the obscure 
pathogenesis.
Interleukin 33 (IL-33), a novel identified member of 
IL-1 family, can be produced in various tissues and cells, 
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responses [7–9]. Through binding to the orphan receptor 
ST2, IL-33 can induce gene expression of Th2-associated 
cytokines, promote Th2 type immune response, and thus 
play important roles in autoimmune diseases [9–11]. In 
rheumatoid arthritis, a higher level of IL-33 was detected 
in synovial fluid, serum, and was correlated with disease 
activity compared to moderate or low activity group or 
healthy controls [12, 13]. Blockade of IL-33/ST2 interac-
tion resulted in dramatically attenuated disease severity 
of rheumatoid arthritis [14]. In systemic lupus erythe-
matosus, elevated serum IL-33 was reported in clinical 
patients and correlated with their disease activity [15–
17]. Disrupting IL-33 pathway resulted in reduced serum 
anti-dsDNA levels, alleviated proteinuria, and attenuated 
lupus nephritis in lupus-prone mice [18]. These findings 
demonstrated a possible role of IL-33 in production of 
IgG autoantibodies and development of autoimmune dis-
eases. However, whether IL-33 functions in AIHA patho-
genesis still remains unclear.
In this study, we investigated the potential role of IL-33 
in AIHA pathogenesis in patients with warm AIHA. 
Our findings revealed an elevated level of serum IL-33 
in patients with AIHA. Of interest, serum IL-33 was 
correlated with disease activity and sensitive to their 
changes in AIHA patients. IL-33 could facilitate produc-
tion of IgG anti-RBC autoantibody from peripheral blood 
mononuclear cells in AIHA patients. Blockade of IL-33 
restrained AIHA incidence and disease activity, while 
enforced IL-33 promoted the development of AIHA. 
These findings assigned IL-33 an important function 
involved in AIHA pathogenesis and provided clues for 
exploring new AIHA therapeutics.
Methods
Patients
Thirty patients diagnosed with AIHA of warm-type 
autoantibodies without treatment were enrolled and 
followed up for 6 months in this study. AIHA diagnosis 
was made with clinical and laboratory hemolytic signs 
plus positive direct anti-globulin test (DAT) as previ-
ously described [1]. Eighteen age- and sex-matched 
healthy controls were studied. Patients were consid-
ered as having active disease when an anemia and at 
least one of the following were present: reticulocyte 
count >2 %, haptoglobin concentration <500 mg/L and 
lactate dehydrogenase (LDH) activity >480  U/L. All 
blood samples and clinical parameters were collected 
after an informed consent. This study was approved 
by the Ethics Committee of Tongji University and per-
formed in accordance with the ethical standards laid 
down in the 1964 Declaration of Helsinki and its later 
amendments.
Cell culture and reagents
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized peripheral blood using Ficoll-
Paque density gradient (GE Healthcare). PBMCs were 
washed with phosphate-buffered saline (PBS) and cul-
tured in RPMI 1640 medium with 10  % FCS and 1  % 
glutamine/penicillin/streptomycin (Life Technologies). 
Recombinant human IL-33 protein was purchased from 
R&D Systems. Anti-human IgM antibody was purchased 
from eBioscience. Recombinant human CD40 Ligand 
(CD40L) was purchased from Life Technologies. For 
in  vitro induction of anti-RBC IgG antibody, PBMCs 
(1 × 106/ml) were cultured with anti-IgM (10 μg/ml) and 
CD40L (10  ng/ml) in the presence or absence of IL-33 
(0–20  ng/ml). Six days later, the supernatants were col-
lected and assayed for IgG antibodies with Human IgG 
total ELISA kit (eBioscience).
Cytokines
Serum level of IL-33 was determined with Human IL-33 
Quantikine ELISA Kit (R&D Systems). IL-4, IL-6 and IL-13 
levels in culture supernatants were also detected with 
Human IL-4, IL-6 and IL-13 Quantikine ELISA Kits (R&D 
Systems) respectively according to the manual’s instructions.
Anti‑RBC IgG antibody
Serum RBC-bound IgG autoantibody was detected with 
flow cytometry as described previously [1, 19]. Briefly, 
RBCs were freshly isolated, washed three times with 
warm PBS and then incubated with FITC anti-IgG anti-
body (Biolegend) at 37  °C. The cells were immediately 
analyzed for percentage of RBC-bound antibody on a 
FACSCalibur flow cytometer (BD Biosciences). Collected 
data were analyzed with FlowJo software (TreeStar).
Induction of murine AIHA
Murine experiments were approved by the Ethics Com-
mittee of Tongji University. Female B6 mice between 8 and 
10  weeks old were purchased from Shanghai Laboratory 
Animal Center and housed in specific pathogen free con-
ditions. As previously described [1], induction of AIHA 
murine model was achieved by immunizing B6 mice with 
2 × 108 rat RBCs on a weekly basis for 10 weeks. For trans-
fusion study, mouse RBCs obtained from naive female B6 
mice were labeled with PKH-26 (Sigma) and injected into 
control mice or those that had developed AIHA through 
tail-vein. Destruction of these syngeneic RBCs was repre-
sented by the clearance of fluorescent RBCs measured by 
flow cytometry. To show the clearance kinetics, injected 
RBCs at 1 min after injection were taken as 100 %, and the 
remaining RBCs were calculated at different time points as 
the average for each group of mice.
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For regulation of IL-33, B6 mice were injected with 
IL-33 neutralizing antibody or recombinant IL-33 respec-
tively with isotype controls (R&D Systems). Briefly, 1 day 
before rat RBCs immunization, mice were intraperito-
neally injected with 100  μg neutralizing antibodies per 
mouse or 2  μg IL-33 per mouse respectively. Injections 
were repeated every 3 days during mice immunization.
Statistical analyses
Quantitative data were expressed as the mean  ±  SD. 
Unpaired t test and Pearson correlation were used for sta-
tistical analyses with PRISM 6.0 (GraphPad Software Inc.). 
A value of P < 0.05 was considered statistically significant.
Results
Serum level of IL‑33 was elevated and correlated 
with disease activity in AIHA patients
We performed ELISA to determine serum levels of IL-33 
in patients with AIHA and healthy controls, and results 
showed a significant higher level of serum IL-33 in 
AIHA patients (Fig.  1a). Further analysis of serum IL-33 
in patients with active AIHA or with AIHA remission 
revealed a relative higher serum IL-33 in patients with 
active AIHA (Fig.  1b). These data indicated an involve-
ment of IL-33 in AIHA pathogenesis. Thus, we detected 
the correlation between serum IL-33 and disease activity 
of active AIHA patients that is presented by the levels of 
reticulocyte count, hemoglobin and lactate dehydrogenase 
(LDH). We found that serum level of IL-33 was closely cor-
related with the level of reticulocyte frequency, negatively 
correlated with the level of hemoglobin and positively cor-
related with the level of LDH activity in AIHA patients 
(Fig. 1c–e). These results demonstrated that serum IL-33 
was closely correlated with disease activity of AIHA.
Serum IL‑33 was sensitive to changes of AIHA disease 
activity
To further explore the correlation of serum IL-33 with 
AIHA disease activity, patients with active AIHA were 
followed up for 6 months and analyzed for their changes 
of serum IL-33 and disease activity. Results showed that 
changes of serum IL-33 were associated with the changes 
of hemoglobin, positively correlated with changes of 
reticulocyte frequency and LDH in AIHA patients 
(Fig.  2a–c). These findings suggested that serum IL-33 
was sensitive to changes of AIHA disease activity.
Serum IL‑33 was associated with anti‑RBC autoantibody 
production
To investigate the possible mechanisms underlying 
the close relationship between serum IL-33 and dis-
ease activity of AIHA patients, we analyzed the correla-
tion of serum IL-33 with anti-RBC autoantibody, which 
plays a central role in AIHA pathogenesis. We found 
that serum IL-33 was positively correlated with the anti-
RBC autoantibody level in AIHA patients (Fig. 3a). Fur-
ther, changes of serum IL-33 was closely associated with 
changes of anti-RBC autoantibody (Fig. 3b). These results 
could partly explain the close correlation of serum IL-33 
with AIHA disease activity and indicated an involvement 
of IL-33 in autoantibody production in AIHA patients.
IL‑33 contributed to anti‑RBC autoantibody production
To further elucidate why serum IL-33 was correlated 
with anti-RBC autoantibody level, we detected the 
effect of IL-33 on IgG anti-RBC antibody production 
in AIHA patients. When PBMCs isolated from patients 
with active AIHA were stimulated with anti-IgM plus 
CD40L in the presence of an increasing dose of recom-
binant human IL-33 protein, we found that IL-33 could 
promote the production of IgG anti-RBC antibody in a 
dose dependent manner (Fig. 4a). Vice vasa, blockade of 
IL-33 efficiently reduced the enhanced production of IgG 
anti-RBC antibody (Fig. 4b). Given the important roles of 
IL-4, IL-6 and IL-13 in antibody production, we further 
detect the production of these cytokines in response to 
IL-33 stimulation. We found that stimulation of PBMCs 
isolated from active AIHA patients with IL-33 protein 
resulted in significant higher production of IL-4, IL-6 and 
IL-13 (Fig. 4c–e). These findings demonstrated that IL-33 
could increase Th2 cytokines release and contribute to 
autoantibody production in patients with AIHA.
Blockade of IL‑33 interfered with incidence and disease 
severity of AIHA
To directly evaluate the potential role of IL-33 in AIHA 
pathogenesis, murine AIHA was induced by immunizing 
B6 mice with rat RBCs with or without IL-33 neutralizing 
antibody. Within 30 mice immunized with rat RBCs, 13 
mice co-injected with isotype control IgG exerted high 
levels of anti-RBC antibody and reticulocytes (Additional 
file  1: Fig. S1, 5A, B). Consistent with this observation, 
these mice showed increased destruction of transfused 
syngeneic mouse RBCs (Fig. 5c). When B6 mice were co-
injected with IL-33 neutralizing antibody, only 5 out of 
30 mice developed AIHA as evidenced by the circulating 
levels of anti-RBC antibody and reticulocytes (Fig.  5a, 
b). Of note, the level of anti-RBC antibody was signifi-
cantly decreased by co-injection with IL-33 neutralizing 
antibody (Fig.  5d). Thus, the destruction of transferred 
syngeneic mouse RBCs was inhibited in IL-33 neutral-
izing antibody co-immunized mice (Fig.  5c). To fur-
ther confirm the effect of IL-33 on AIHA pathogenesis, 
groups of B6 mice were immunized with rat RBCs plus 
recombinant IL-33 protein. Results showed that enforced 
IL-33 significantly enhanced the incidence of AIHA 
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and elevated the generation of IgG anti-RBC antibody 
(Fig.  5e–h). These results regarded IL-33 as an impor-
tant regulator in AIHA pathogenesis and suggested that 
blockade of IL-33 was a promising strategy to control 
AIHA disease.
Discussion
AIHA is an autoimmune disorder caused by production 
of autoantibody that directed against self red blood cells 
[20, 21]. Therefore, intervention of anti-RBC autoan-
tibody production is essential for AIHA treatment. 
Fig. 1 Elevated serum IL-33 in AIHA patients was correlated with AIHA disease activity. a Serum IL-33 was determined in AIHA patients (n = 30) 
and healthy controls (n = 18); b serum IL-33 was detected in patients with active AIHA (n = 17) or with inactive AIHA (n = 13); c–e the correlation 
between serum IL-33 and levels of reticulocyte count (c), hemoglobin (d) and lactate dehydrogenase (LDH, e) was analyzed in active AIHA patients 
(n = 17). One dot represented the result from one patient
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Currently, therapeutic options for AIHA are usually cor-
ticosteroids, splenectomy, intravenous immunoglobulins, 
plasma-exchange and other immunosuppressive drugs, 
which are non-specific and have considerable side effects 
[2, 22–24]. Rituximab, a monoclonal antibody against 
the protein CD20 and can destroy immune system B 
cells, has been tested in treatment of AIHA [3, 25–27]. 
However, autoantibody production in AIHA, especially 
IgG autoantibody that accounts for warm AIHA devel-
opment, requires involvement of T helper cells for B cell 
responses. Thus, modulation of T cell responses could be 
an optimal strategy for AIHA treatment.
IL-33 is a newly described cytokine of IL-1 super-
family and is reported to be involved in T cell medi-
ated immune responses [15]. Herein, we reported that 
serum IL-33 was positively associated with and sensi-
tive to anti-RBC autoantibody levels in AIHA patients. 
Fig. 2 IL-33 was sensitive to AIHA disease activity. Patients with active 
AIHA (n = 17) were followed up and analyzed for the changes of 
serum IL-33, reticulocyte count, hemoglobin and LDH. Delta repre-
sented the different values between post-follow and pre-follow. The 
correlation between changes of serum IL-33 and changes of hemo-
globin (a), changes of reticulocyte count (b), and changes of LDH (c) 
was detected. One dot represented the result from one patient
Fig. 3 IL-33 was associated with anti-RBC antibody production. a The 
correlation of serum IL-33 with anti-RBC antibody level was deter-
mined in AIHA patients (n = 17); b the correlation between changes 
of serum IL-33 and changes of anti-RBC antibody production was 
analyzed in AIHA patients (n = 17). One dot represented the result 
from one patient
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In contrast, serum levels of sST2 in AIHA patients were 
generally comparable with that in healthy individuals 
(Additional file 1: Fig. S2), conferring an active function 
of serum IL-33 in AIHA patients. Further, IL-33 could 
promote the release of Th2 cytokines and the produc-
tion of IgG anti-RBC autoantibody. Thus, accumula-
tion of IL-33 in peripheral blood could facilitate the 
anti-RBC autoantibody production, which provided a 
new mechanism through which the autoantibody pro-
duction was exacerbated in AIHA patients. Therefore, it 
is reasonable to speculate that IL-33 might be a promis-
ing target for controlling autoantibody production and 
thus restrains AIHA development. In support, we dem-
onstrated that IL-33 could promote the development of 
Fig. 4 IL-33 promoted anti-RBC antibody production. a PBMCs from AIHA patients (n = 6) were stimulated with anti-IgM, CD40L in the presence of 
indicated dose of IL-33 for 6d, and then assayed for IgG antibody production. One dot represented the result from one patient; b PBMCs from AIHA 
patients (n = 5) were stimulated with anti-IgM, CD40L plus IL-33 (20 ng/ml) in the presence of IL-33 neutralizing antibody or control antibody (2 μg/
ml) for 6d, and detected for IgG antibody; c–e PBMCs from AIHA patients (n = 4) were stimulated with IL-33 (20 ng/ml) for 72 h, followed by detec-
tion for production of IL-4, IL-6 and IL-13 in supernatants
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AIHA, and more importantly, blockade of IL-33 effec-
tively reduced the incidence of AIHA and ameliorated 
AIHA disease severity. These results extended previ-
ous studies that implicated IL-33 based therapeutics in 
treatment of a range of diseases including autoimmune 
disease [9, 15].
Herein, we revealed that serum IL-33 was significantly 
elevated in patients with AIHA and closely correlated 
with the disease activity. Our results were consistent 
with previous studies that showed elevated serum IL-33 
in autoimmune diseases [28–30]. The increased levels 
of IL-33 in AIHA patients might result from destruc-
tive RBCs and macrophages because RBCs could store 
and release IL-33, and macrophages served as important 
scavengers [31, 32]. Our findings suggested that serum 
level of IL-33 might serve as a potential biomarker for 
AIHA disease activity. Besides, serum IL-33 was sensi-
tive to changes of disease activity and anti-RBC autoan-
tibody production in AIHA patients, indicating that 
serum IL-33 was also a promising indicator for monitor-
ing the efficiency of clinical practice. To our knowledge, 
this is the first study that described the elevated serum 
IL-33 and its close correlation with disease activity in 
AIHA patients. Considering the facts that around 5  % 
of AIHA remains DAT-negative and treatment of AIHA 
is currently not evidence-based [33], new biomarkers 
that have diagnostic values or that can be used to assess 
treatment response could be helpful in clinical practice.
In this study, we observed an interesting effect of IL-33 
on anti-RBC antibody production, which might due to 
increased secretion of Th2 cytokines. In fact, we found 
diminished levels of Th2 cytokines in AIHA mice co-
injected with anti-IL-33 neutralizing antibody, and ele-
vated levels Th2 cytokines in AIHA mice co-injected with 
IL-33 (Additional file 1: Fig. S3A, B). These Th2 cytokines 
are considered important for supporting B cell responses. 
We observed elevated frequency of B cells within PBMCs 
after stimulation with IL-33 in vitro (Additional file 1: Fig. 
S4A), and defective development of germinal center B 
cells in AIHA mice co-injected with anti-IL-33 neutraliz-
ing antibody (Additional file 1: Fig. S4B). Further, disrupt 
IL-6 signaling with neutralizing antibody significantly 
abrogated the effect of IL-33 on IgG anti-RBC antibody 
production (Additional file 1: Fig. S5). These findings sug-
gested important roles of IL-33-mediated Th2 cytokines 
in AIHA pathogenesis. It is well acknowledged that ST2 
is highly expressed on group 2 innate lymphoid cells and 
T helper 2 cells [34]. Therefore, we proposed that pro-
duction of anti-RBC antibody in AIHA patients was, at 
least in part, dependent on ST2+ T cells, which released 
increased levels of Th2 cytokines in response to IL-33 
and thus support B cell responses. The destructive RBCs 
and engaged macrophages would promote the accumu-
lation of IL-33 and feed-forward the generation of anti-
RBC antibody in AIHA patients.
Conclusions
Here we reported an elevated serum IL-33 and its contri-
bution to anti-RBC autoantibody production in patients 
with AIHA. IL-33 was a potential biomarker for moni-
toring disease activity and treatment response in AIHA 
patients. Targeting IL-33 was a promising therapeutic 
strategy for AIHA patients in clinical practice.
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